AT-9283

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAT-9283
Drug Alias NameAT-9283
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitorsBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase JAK2 inhibitors +[5] 
TargetsTyrosine-protein kinase JAK2Bcr-Abl tyrosine kinaseSerine/threonine-protein kinase Aurora-A +[5] 
Therapy Area/IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursPrimary MyelofibrosisMyelodysplastic Syndromes +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBank